1. U.S. Food and Drug Administration Center for Drug Evaluation and Research (2016) Physiologically based pharmacokinetic analyses—format and content: guidance for industry, draft. U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Rockville, MD
2. Chen GC, Enayati P, Tran T, Lee-Henderson M, Quan C, Dulai G, Arnott I, Sul J, Jutabha R (2006) Sensitivity and inter-observer variability for capsule endoscopy image analysis in a cohort of novice readers. World J Gastroenterol 12(8):1249–1254.
https://doi.org/10.3748/wjg.v12.i8.1249
3. Strategies, approaches, and challenges in model-informed drug development (MIDD) (2017). FDA briefing document—Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting, Rockville, MD
4. WHO (2010) Harmonization project document no. 9: characterization and application of physiologically based pharmacokinetic models in risk assessment. World Health Organization International Programme on Chemical Safety Harmonization Project, Ottawa, ON
5. McNally K, Cotton R, Loizou GD (2011) A workflow for global sensitivity analysis of PBPK models. Front Pharmacol 2:31.
https://doi.org/10.3389/fphar.2011.00031